Iceland· IS-EU/1/21/1599/001-002
Vyepti
A eptinezumab product containing eptinezumabum inn, registered in Iceland by H. Lundbeck A/S*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Eptinezumabum INN
- Manufacturer
- H. Lundbeck A/S*
- Country
- Iceland (IS)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean0851361 ml x1 hglISK 179463
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- BelgiumVyepti 100 mgH. Lundbeck
- IrelandVYEPTI 100 mg concentrate for solution for infusionH. Lundbeck A/S
- NorwayVyeptiH. Lundbeck A/S
- SwedenVyepti 100 mg Koncentrat till infusionsvätska, lösningH. Lundbeck A/S
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db3420b0-9342-4d03-863a-0195546c0705 GET /v1/drugs/db3420b0-9342-4d03-863a-0195546c0705?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "N02CD05",
"marketed": true,
"strength": "100 mg",
"ma_number": "EU/1/21/1599/001-002",
"substance": "Eptinezumabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44585"
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.